side effects of semaglutide and tirzepatide caused roughly half as many patients to stop treatment because gastrointestinal as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Why You Might Tolerate One

Legal and Regulatory Standing Compounded semaglutide is allowed during shortages of FDA-approved options

A therapy area market with $131bn of global value would immediately become the fourth member of the mega-therapy areas which are substantially more valuable, and drive more of the value growth, of the global prescription medicine market

Depression was reported in a small percentage of patients, but at frequencies consistent with the general population

While more research is needed to fully understand the mechanisms at play, these findings suggest a promising link between glutathione and blood pressure management